Maligne Lymphome: Individualisierte Therapie in Abhängigkeit von biologischen und klinischen Risikofaktoren

Schlüsselwörter

Hodgkin-Lymphom - follikuläres Lymphom - Morbus Waldenström - Mantelzell-Lymphom

Keywords

hodgkin's lymphoma - follicular lymphoma - Waldenstroem's macroglobulinemia - mantle cell lymphoma

Literatur

• 1 Ardeshna KM, Quian W, Smith P. et al . An intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2, and 3a): a preliminary analysis. 52nd ASH Annual Meeting.  2010, Abstract 6; 
• 2 Chen R, Gopal A, Smith S. et al . Results of a pivotal phase 2 study of Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory Hodgkin Lymphoma.  52nd ASH Annual Meeting. 2010, Abstract 283; 
• 3 Fernandez V, Salamero O, Espinet B. et al . Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma.  Cancer Res. 2010;  70 1408-1418
• 4 Feuerlein K, Zucca E, Ghielmini M. First-line treatment of follicular lymphoma. A patient-oriented algorithm.  Leuk Lymphoma. 2009;  50 225-234
• 5 Fowler N, Sharman J P, Smith S M. et al . The Btk inhibitor, PCI-32 765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study.  52nd ASH Annual Meeting. 2010, Abstract 964; 
• 6 Ghobrial I M, Hong F, Padmanabhan S. et al . Phase II trial of weekly Bortezomib in combination with Rituximab in relapsed or relapsed and refractory waldenström macroglobulinemia.  JCO. 2010;  28 1422
• 7 Kahl B, Byrd J C, Flinn I. et al . Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-Kinase P110δ in patients with relapsed or refractory non-hodgkin lymphoma.  ASH. 2010 Abstract 1777; 
• 8 Kastritis E, Kyrtsonis M CH, Hadjiharissi E. et al . Validation of the International Prognostic Scoring System (IPSS) for waldenstromŽs macroglobulinemia (WM) and the importance of serum lactat dehydrogenase (LDH).  Leuk Res. 2010;  34 1340
• 9 Martinelli G, Schmitz S F, Utinger U. et al . Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.  JCO. 2010;  28 4480
• 10 Olivier H, Hoster E, Walewski J. et al . Alternating courses of 3 x CHOP and 3 X DHAP plus Rituximab followed by a high dose AraC containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 course CHOP plus Rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of die MCL Younger Trial of the European mantle cell lymphoma network (MCL net).  ASH. 2010 Abstract 110; 
• 11 Peyrade F, Jardin F, Gisselbrecht C. et al . Rituximab and reduced dose CHOP (R-mini-CHOP) for patients over 80 years with diffuse large B-cell lymphoma (DLBCL).  52nd ASH Annual Meeting. 2010 Abstract 853; 
• 12 Pott C, Hoster E, Delfau-Larue M N. et al . Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.  Blood. 2010;  115 3215
• 13 Pugh T J, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis.  Cancer. 2010;  116 3843
• 14 Recher C, Coiffier B, Haioun C. et al . A prospective randomized study comparing dose intensive immunochemotherapy with R-ACVBP vs. standard R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL).  52nd ASH Annual Meeting. 2010, Abstract 109; 
• 15 Salles G A, Catalano J, Feugier P. et al . Updated results of the PRIMA Study confirms the benefit of 2-years Rituximab maintenance in follicular lymphoma patients responding to immunochemotherapy.  52nd ASH Annual Meeting. 2010, Abstract 1788; 
• 16 Scholz C, Pinto A, Likhesch W. et al . 90Yttrium-Ibritumomab-Tiuxetan as first-line treatment of follicular lymphoma.  52nd ASH Annual Meeting. 2010, Abstract 593;